Palaniappan Ramanathan
Overview
Explore the profile of Palaniappan Ramanathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
604
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyer M, Ramanathan P
Methods Mol Biol
. 2024 Nov;
2877:387-405.
PMID: 39585636
Single-cell technologies are continually evolving with emerging methods that are gradually uncovering the central DNA-RNA-protein dogma. Single-cell RNA sequencing is one arm of a multi-omic approach that achieves an astounding...
2.
Ahmad A, Tigabu B, Ivanov A, Jerebtsova M, Ammosova T, Ramanathan P, et al.
Res Sq
. 2023 Jun;
PMID: 37333330
The Ebola virus (EBOV) transcriptional regulation involves host protein phosphatases PP1 and PP2A, which dephosphorylate the transcriptional cofactor of EBOV polymerase VP30. The 1E7-03 compound, which targets PP1, induces VP30...
3.
Ramanathan P, Tigabu B, Santos R, Ilinykh P, Kuzmina N, Vogel O, et al.
Viruses
. 2023 May;
15(5).
PMID: 37243162
Members of the Ebolavirus genus demonstrate a marked differences in pathogenicity in humans with Ebola (EBOV) being the most pathogenic, Bundibugyo (BDBV) less pathogenic, and Reston (RESTV) is not known...
4.
Kuzmin I, Ramanathan P, Basler C, Bukreyev A
Front Virol
. 2022 Oct;
1.
PMID: 36237518
Bats constitute a large and diverse group of mammals with unique characteristics. One of these is the ability of bats to maintain various pathogens, particularly viruses, without evidence of disease....
5.
Ilinykh P, Periasamy S, Huang K, Kuzmina N, Ramanathan P, Meyer M, et al.
NPJ Vaccines
. 2022 Apr;
7(1):47.
PMID: 35468973
Respiratory tract vaccination has an advantage of needle-free delivery and induction of mucosal immune response in the portal of SARS-CoV-2 entry. We utilized human parainfluenza virus type 3 vector to...
6.
Meyer M, Wang Y, Edwards D, Smith G, Rubenstein A, Ramanathan P, et al.
J Clin Invest
. 2021 Aug;
131(20).
PMID: 34449440
The mRNA-1273 vaccine is effective against SARS-CoV-2 and was granted emergency use authorization by the FDA. Clinical studies, however, cannot provide the controlled response to infection and complex immunological insight...
7.
Hoehn K, Ramanathan P, Unterman A, Sumida T, Asashima H, Hafler D, et al.
J Immunol
. 2021 May;
206(12):2785-2790.
PMID: 34049971
Protective immunity against COVID-19 likely depends on the production of SARS-CoV-2-specific plasma cells and memory B cells postinfection or postvaccination. Previous work has found that germinal center reactions are disrupted...
8.
Meyer M, Wang Y, Edwards D, Smith G, Rubenstein A, Ramanathan P, et al.
bioRxiv
. 2021 Feb;
PMID: 33532780
The mRNA-1273 vaccine was recently determined to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interim Phase 3 results. Human studies, however, cannot provide the controlled response...
9.
Zhu J, Ramanathan P, Bishop E, ODonnell V, Gladue D, Borca M
PLoS One
. 2019 Nov;
14(11):e0223955.
PMID: 31725732
African swine fever (ASF) is a swine disease caused by a large, structurally complex, double-stranded DNA virus, African swine fever virus (ASFV). In domestic pigs, acute infection by highly virulent...
10.
Younan P, Santos R, Ramanathan P, Iampietro M, Nishida A, Dutta M, et al.
PLoS Pathog
. 2019 Oct;
15(10):e1008068.
PMID: 31648236
Ebola virus (EBOV) infections are characterized by a pronounced lymphopenia that is highly correlative with fatalities. However, the mechanisms leading to T-cell depletion remain largely unknown. Here, we demonstrate that...